Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug. The post Axsome Aims…

Read More

What has been the main impact of MFN?

It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous ​10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer. You can read the full…

Read More

This Test Can See a Heart Attack in Your Future

A long list of Lynda Hollander’s paternal relatives had heart disease, and several had undergone major surgeries. So when she hit her mid-50s and saw her cholesterol levels creeping up after menopause, she said, “I didn’t want to take a chance.” A cardiologist told Hollander that based on factors like age, sex, cholesterol, and blood…

Read More

Google’s Olympics Misstep and the Real AI Opportunity

While Google showcases AI’s ability to mimic human sentimentality, it misses the forest for the trees. The real innovation, the true potential of AI, lies not in replacing human expression but in enhancing human lives, particularly those of our rapidly aging population. The post Google’s Olympics Misstep and the Real AI Opportunity appeared first on…

Read More